Repositioning Candidate Details
| Candidate ID: | R0076 |
| Source ID: | DB00204 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Dofetilide |
| Synonyms: | beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; Dofetilide |
| Molecular Formula: | C19H27N3O5S2 |
| SMILES: | CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1 |
| Structure: |
|
| DrugBank Description: | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. |
| CAS Number: | 115256-11-6 |
| Molecular Weight: | 441.565 |
| DrugBank Indication: | For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter ) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm |
| DrugBank Pharmacology: | Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors. |
| DrugBank MoA: | The mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conduction in the accessory pathway). |
| Targets: | Potassium voltage-gated channel subfamily H member 2 inhibitor; Potassium channel subfamily K member 2 inhibitor; ATP-sensitive inward rectifier potassium channel 12 inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |